The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes

Panagiotis Tsikripis, Dimitrios Papaconstantinou, Chryssanthi Koutsandrea, Michalis Apostolopoulos, Ilias Georgalas, Panagiotis Tsikripis, Dimitrios Papaconstantinou, Chryssanthi Koutsandrea, Michalis Apostolopoulos, Ilias Georgalas

Abstract

Purpose: To evaluate the effect of prostaglandin analogs (PGAs) on the biomechanical properties (corneal hysteresis [CH], corneal resistance factor [CRF]) and central corneal thickness (CCT) of patients with open-angle glaucoma.

Methods: A total of 108 eyes were prospectively included for repeated measurements of intraocular pressure (IOP) with Goldmann applanation tonometry (GAT) and ocular response analyzer (ORA), CCT, followed by CH and CRF measurements by the ORA, during the same visit. Of these, 66 were treated with latanoprost, and 42 were treated with latanoprost and timolol. IOP, CH, CRF, and CCT were measured before treatment and at 6-month intervals.

Results: It appears that under local PGA treatment, IOP values decreased and CH and CCT significantly increased, whereas CRF did not. CCT slightly but significantly increased at all time points of the study (0.50-3.00 μm and 1.50-5.50 μm), and we observed a constant significant increase in CH (0.4-0.7 mmHg and 0.65-0.95 mmHg). Concerning the correlation of GAT IOP with CCT and CH, it was found that at the time points 0, 1, and 2 there were statistically significant correlations.

Conclusion: The changes of CCT and CH under PGA treatment in clinical practice may influence IOP measurements and patient follow-up significantly. This should be investigated further to confirm the relationship between corneal properties and treatment of open-angle glaucoma.

Keywords: central corneal thickness; corneal hysteresis; corneal resistance factor; glaucoma; intraocular pressure; ocular response analyzer; prostaglandins.

Figures

Figure 1
Figure 1
Intraocular pressure (IOP) values during the study for the latanoprost group. Abbreviation: GAT, goldmann applanation tonometry.
Figure 2
Figure 2
Intraocular pressure (IOP) values during the study for the latanoprost and timolol group. Abbreviation: GAT, goldmann applanation tonometry.
Figure 3
Figure 3
Central corneal thickness (CCT) evolution during the study, sorted by treatment.
Figure 4
Figure 4
Corneal hysteresis (CH) evolution during the study, sorted by treatment. Abbreviation: CCT, central corneal thickness.

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
    1. Ang GS, Bochmann F, Townend J, Azuara-Blanco A. Corneal biomechanical properties in primary open angle glaucoma and normal tension glaucoma. J Glaucoma. 2008;17:259–262.
    1. Mangouritsas G, Mourtzoukos S, Mantzounis A, Alexopoulos L. Comparison of Goldmann and Pascal tonometry in relation to corneal hysteresis and central corneal thickness in non-glaucomatous eyes. Clin Ophthalmol. 2011;5:1071–1077.
    1. Kohlhaas M, Boehm AG, Spoerl E, Pürsten A, Grein HJ, Pillunat LE. Effect of central corneal thickness, corneal curvature, and axial length on applanation tonometry. Arch Ophthalmol. 2006;124:471–476.
    1. Argus WA. Ocular hypertension and central corneal thickness. Ophthalmology. 1995;102:1810–1812.
    1. Congdon NG, Broman AT, Bandeen-Roche K, Grover D, Quigley HA. Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol. 2006;141:868–875.
    1. Herndon L, Weizer J, Stinnett S. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol. 2004;122:17–21.
    1. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972.
    1. Lass JH, Eriksson GL, Osterling L, Simpson CV. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology. 2001;108:264–271.
    1. Wu KY, Wang HZ, Hong SJ. Effect of latanoprost on cultured porcine stromal cells. Curr Eye Res. 2005;30:871–879.
    1. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112–115.
    1. Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol. 2010;128:466–471.
    1. Mietz H, Esser JM, Welsandt G, et al. Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003;44:5182–5188.
    1. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. 1998;67:179–191.
    1. Sagara T, Gaton D, Lindsey J, Gabelt B, Kaufman P, Weinberg R. Topical prostaglandin F2a treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:798–801.
    1. Wang N, Lindsey JD, Angert M, Weinreb RN. Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures. Curr Eye Res. 2001;22:198–207.
    1. Liu Y, Yanai R, Lu Y, Hirano S, Sagara T, Nishida T. Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma. 2006;15:255–259.
    1. Shih CY, Graff Zivin JS, Trokel SL, Tsai JC. Clinical significance of central corneal thickness in the management of glaucoma. Arch Ophthalmol. 2004;122:1270–1275.
    1. Avetisov SE, Bubnova IA, Antonov AA. [Investigation of the biomechanical properties of the cornea in patients with normotensive and primary open-angle glaucoma.] Vestn Oftalmol. 2008;124:14–16. Russian.
    1. Schroeder B, Hager A, Kutschan A, Wiegand W. [Measurement of viscoelastic corneal parameters (corneal hysteresis) in patients with primary open angle glaucoma.] Ophthalmologe. 2008;105:916–920. German.
    1. Wells AP, Garway-Heath DF, Poostchi A, Wong T, Chan KC, Sachdev N. Corneal hysteresis but not corneal thickness correlates with optic nerve surface compliance in glaucoma patients. Invest Ophthalmol Vis Sci. 2008;49:3262–3268.
    1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.
    1. Bochmann F, Ang GS, Azuara-Blanco A. Lower corneal hysteresis in glaucoma patients with acquired pit of the optic nerve (APON) Graefes Arch Clin Exp Ophthalmol. 2008;246:735–738.
    1. Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg. 2005;31:156–162.
    1. Touboul D, Roberts C, Kérautret J, et al. Correlations between corneal hysteresis, intraocular pressure, and corneal central pachymetry. J Cataract Refract Surg. 2008;34:616–622.
    1. Brandt JD, Beiser JA, Gordon MO, Kass MA. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004;138:717–722.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj